Adjunctive pascolizumab in rifampicin-susceptible pulmonary tuberculosis: proof-of-concept, partially-randomised, double-blind, placebo-controlled, dose-escalation trial.
Nicholas Iain PatonMeera GurumurthyQingshu LuFrancesca LeekPhilip KwanHiromi W L KohJames MoltonLalaine MorteraSullian NavalZamzurina Abu BakarYong-Kek PangLionel LumTow Keang LimGail B CrossGanesh LekurwaleHyung Won ChoiVeonice AuJohn ConnollyMartin HibberdJustin A Greennull nullPublished in: The Journal of infectious diseases (2024)
There was no evidence to suggest blocking IL-4 was unsafe. Preliminary efficacy findings are consistent with animal models. This supports further investigation of adjunctive anti-IL-4 interventions for tuberculosis in larger phase 2 trials.
Keyphrases
- pulmonary tuberculosis
- placebo controlled
- double blind
- phase iii
- phase ii
- mycobacterium tuberculosis
- study protocol
- clinical trial
- open label
- phase ii study
- physical activity
- randomized controlled trial
- radiation therapy
- emergency department
- hiv infected
- squamous cell carcinoma
- rectal cancer
- electronic health record